Literature DB >> 28044124

Aberrant Expression Profile of Long Noncoding RNA in Human Sinonasal Squamous Cell Carcinoma by Microarray Analysis.

Ling-Zhao Meng1, Ju-Gao Fang2, Jing-Wu Sun1, Fan Yang1, Yong-Xiang Wei1.   

Abstract

Objectives. This study aimed to identify aberrantly expressed long noncoding RNAs (lncRNAs) profile of sinonasal squamous cell carcinoma (SSCC) and explore their potential functions. Methods. We investigated lncRNA and mRNA expression in SSCC and paired adjacent noncancerous tissues obtained from 6 patients with microarrays. Gene ontology (GO) analysis and pathway analysis were utilized to investigate the gene function. Gene signal-network and lncRNA-mRNA network were depicted. Quantitative real-time polymerase chain reaction (qRT-PCR) was utilized to validate 5 lncRNAs in a second set of paired SSCC and adjacent noncancerous tissues obtained from 22 additional patients. Results. We identified significantly differentially expressed lncRNAs (n = 3146) and mRNAs (n = 2208) in SSCC relative to noncancerous tissues. The GO annotation indicated that there are some core gene products that may be attributed to the progress of SSCC. The pathway analysis identified many pathways associated with cancer. The results of lncRNA-mRNA network and gene signal-network implied some core lncRNAs/mRNAs might play important roles in SSCC pathogenesis. The results of qRT-PCR showed that all of the 5 lncRNAs were differentially expressed and consistent with the microarray results. Conclusion. Our study is the first screening and analysis of lncRNAs expression profile in SSCC and may offer new insights into pathogenesis of this disease.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 28044124      PMCID: PMC5156798          DOI: 10.1155/2016/1095710

Source DB:  PubMed          Journal:  Biomed Res Int            Impact factor:   3.411


1. Introduction

Head and neck squamous cell carcinoma is the sixth most common malignancy worldwide. Sinonasal squamous cell carcinomas (SSCC) are rare tumor, estimated to account for approximately 3–6% of all head and neck squamous cell carcinomas. SSCC originate in the respiratory epithelium of the sinonasal cavities [1]. Approximately 60% of SSCC arise in the maxillary sinus, 20–30% in the nasal cavity, 10–15% in the ethmoid sinuses, and ~1% in the frontal and sphenoid sinuses [2, 3]. Environmental factors, such as wood dust and textile, may play a critical role in the development of SSCC. As in other head and neck squamous cell carcinomas, smoking is a known risk factor [4]. Males who have greater occupational exposure to carcinogens are affected twice as often as females. It is controversial that chronic inflammatory sinus disease could influence development of SSCC. Human papilloma virus (HPV) types 16 and 18 may be implicated in malignant transformation of inverted papillomas [5]. The low incidence of SSCC combined with their nonspecific symptoms often leads to a critical delay in diagnosis. Treatment for SSCC is usually primarily surgical with adjuvant radiotherapy and sometimes with adjuvant chemotherapy for all except small tumors [1]. Surgical management of SSCC is of great challenge due to its anatomical complexity, especially advanced SSCC involving eye, skull base, or infratemporal fossa. In spite of major advances in the therapy of SSCC, including surgery and chemoradiotherapy methods, the 5-year survival rate is still very low (30–50%) [1]. Long noncoding RNAs (lncRNAs) are a subset of noncoding RNAs >200 nucleotides in length and do not encode any protein. Due to the poor evolutionary conservation relative to the protein coding regions of the genome, lncRNAs were once considered as transcriptional noise or junk and have not been well studied historically. Recently, considerable evidence has been accumulating showing that aberrant expression of lncRNAs contributes to the development of human cancers [6-8]. lncRNAs contribute to tumor development through numerous different cellular processes, ranging from transcriptional and posttranscriptional regulation of relevant genes to the control of cell cycle distribution, cell differentiation, and epigenetic modifications. lncRNAs may be involved in cell proliferation, tumor invasion, metastasis, or apoptosis process. lncRNAs are pervasively transcribed and have a critical role in genome regulation [6, 7, 9]. However, to our knowledge, little is known about lncRNAs expression profile in SSCC, and the potential pathways regulating SSCC invasiveness remain poorly understood. This pilot study aimed to identify aberrantly expressed lncRNAs profile of SSCC and explore their potential functions. This study will help us to understand the tumorigenesis and development of SSCC and provide some new biomarkers that may be critical to the developmental cascade.

2. Materials and Methods

2.1. Patients and Tissue Samples

A total of 28 pairs of primary SSCC tissues and their paired adjacent noncancerous sinonasal tissues were surgically obtained from adult patients undergoing treatment at Anzhen Hospital and Tongren Hospital (two tertiary academic centers in Beijing, China) between January 2013 and August 2014. During surgery, fresh tumor tissue and paired noncancerous tissue isolated from at least 2 cm away from the tumor border (sometimes contralateral normal sinonasal mucosa) were collected in the operating room and processed immediately in liquid nitrogen within 15 minutes and then stored in RNA Fixer Reagent (Bioteke, Beijing, China) at −80°C prior to total RNA extraction. 6 pairs of tissues underwent microarray analysis (Table 1) and the remaining 22 tissues were used in validation studies by quantitative real-time polymerase chain reaction (qRT-PCR). Tobacco smoke was the most common exposure factor, about 66.67% (4/6) in the microarray analysis series and 63.64% (14/22) in the PCR validation series. Wood dust was the second common exposure factor, about 33.33% (2/6) in the microarray analysis series and 18.18% (4/22) in the PCR validation series. Other exposure factors were chronic sinusitis (3/22) and leather dust (1/22). All cases were reviewed by two or more independent pathologists, and none of the patients had been previously treated with radiotherapy or chemotherapy. All tumor staging was determined according to the tumor-node-metastasis (TNM) staging criteria of American Joint Committee on Cancer (AJCC), 2010.
Table 1

Clinical parameters of 6 SSCC patients that underwent lncRNA expression profiling.

Specimen number ofSSCC tissuesGenderAge (years)Exposure factorTNM stageHistologic differentiationSpecimen number of noncancerous tissues
F5Male81Wood dustT1N0M0WellG2
F9Male46Tobacco smokeT3N0M0PoorlyG10
A3Male52Tobacco smokeT4N0M0ModeratelyB2
D6Male72Wood dustT4N0M0ModeratelyF1
F2Male52Tobacco smokeT3N0M0ModeratelyH2
D2Male66Tobacco smokeT3N0M0Moderately to PoorlyD9
The Ethics Committee in Clinical Research of Capital Medical University approved this study, and written informed consent was provided by all patients.

2.2. Transcript Analysis

RNA extraction was carried out using standard methods (Life Technologies; RNA Easy, Qiagen, Valencia, CA, USA). Total RNA was quantified by the NanoDrop ND-2000 (Thermo Scientific) and RNA integrity was assessed using Agilent Bioanalyzer 2100 (Agilent Technologies). Microarray profiling was conducted with the Agilent Human lncRNA (4∗180 K, Design ID: 062918) in this experiment and data analysis of the 12 samples has been completed in the laboratory of the KPS Biotechnology Company in Beijing, China. The sample labeling, microarray hybridization, and washing were performed based on the manufacturer's standard protocols. Briefly, total RNA was transcribed to double strand cDNA and then synthesized into cRNA and labeled with Cyanine-3-CTP. The labeled cRNAs were hybridized onto the microarray. After washing, the arrays were scanned with the Agilent Scanner G2505C. Feature Extraction software (version 10.7.1.1, Agilent Technologies) was used to analyze array images to obtain raw expression data, which was processed using GeneSpring. Briefly, raw data was normalized with the quantile algorithm. Probes which had at least 1 out of 2 conditions having 75% flags in “p” were selected for further data analysis. Differentially expressed gene transcripts were later identified. We set a standard threshold set for up- and downregulated genes of a fold change ≥2.0 and a p value ≤0.05. Hierarchical clustering was performed to display expression patterns among samples. Briefly, we calculated the distance matrix between the gene expression data. Once this matrix of distances was computed, clustering begins. Agglomerative hierarchical processing consisted of repeated cycles where the two closest remaining items (those with the smallest distance) are joined by a node/branch of a tree, with the length of the branch set to the distance between the joined items. The two joined items were removed from the list of items being processed and replaced by an item that represents the new branch. The distances between this new item and all other remaining items were computed, and the process was repeated until only one item remained.

2.3. lncRNA-mRNA Coexpression Networks

R function cor. test (a test for association/correlation between paired samples) was utilized to compute Pearson's correlation coefficient to measure the gene coexpression. The lncRNAs/mRNAs (Pearson correlation coefficients ≥0.93) were selected to draw the network with Cytoscape. According to these data, we built lncRNA-mRNA network using the correlation coefficients to examine interactions between lncRNA and mRNA. The value of “degree” in coexpression network indicated that one mRNA/lncRNA might be correlated with several lncRNAs/mRNAs.

2.4. GO Analysis and KEGG Pathway Analysis

GO analysis was applied to analyze the main function of the differential expression genes according to the GO database. Pathway analysis was used to find out the significant pathway of the differential genes according to KEGG. We used Fisher's exact test and χ 2 tests to select the significant pathway, and the threshold of significance was defined by p value and false discovery rate (FDR). The enrichment Re was calculated using standard methods with a p value (hypergeometric-p value) denoting the significance of the pathway correlated with the conditions, with a threshold of p < 0.05, adjusted for multiple comparisons.

2.5. Gene Signal-Network

Gene-gene interaction network was constructed based on the data of differentially expressed genes. Java was utilized to build and analyze molecular networks. After parsing the whole KEGG database, selected genes involved in relevant pathways were extracted, and the study pathway network was generated with the help of the pathway topology in the KEGG database.

2.6. qRT-PCR Analysis

Total RNA was extracted and purified using standard methods (Life Technologies; RNA Easy, Qiagen, Valencia, CA, USA). M-MLV reverse transcription (Promega) was utilized to synthesize cDNA. 5 lncRNA expressions in sinonasal tissues were measured by qRT-PCR which was performed on the ABI 7500 qPCR system with the primer pairs listed in Table 2. The raw quantifications were normalized to the beta-actin gene values for each sample and fold changes were shown as mean ± SD in three independent experiments, each in triplicate.
Table 2

The primer sequences in the present study.

lncRNA nameForward primers (5′-3′)Reverse primers (5′-3′)Amplicon size (bp)
NONHSAT066780GGAACCAGCTACTCCACACCCCTACCCAGGCCAAGTTCTG182
TCONS_l2_00030809TGAAAAACCACAGGCCCACTACAAACATGTCTCTCATCAGCAC78
NONHSAT125629GATTTGAATCGGTCGGCGGAGGCATTTCCTCTCACGCC284
NONHSAG040260ATGCCCTACGAATGTGGACCTCGGCCCACTGCTAAACATC218
NONHSAG043195GGGAAGGCTGCCTATGAAGGAATTCGGGGTTGCAGGTTCT184

2.7. Statistical Analysis

All data were expressed as the mean ± SD or proportions where appropriate. Expression levels between SSCC tissues and adjacent nontumor tissues were analyzed by paired-sample t-tests. p values <0.05 (two-tailed) indicated statistical significance. The Statistical Program for Social Sciences (SPSS) 21.0 software (SPSS, Chicago, IL, United States) was employed to perform all of the statistical analyses.

3. Results

3.1. Overview of lncRNA Profile

Out of a collection of 78,243 lncRNAs and 32,776 mRNAs probes, our lncRNA expression profile of 6 malignant sinonasal tissue and corresponding normal tissue samples from patients with SSCC indicated dysregulation of 6.73% (821 upregulated and 1103 downregulated transcripts) of mRNA and 4.02% (1174 upregulated and 1098 downregulated transcripts) of lncRNA transcripts in SSCC tissues (fold change >2, p < 0.05) (Figure 1). As expected, the lncRNA and mRNA expression profiles allowed distinguishing malignant and normal tissue samples accurately based on the molecular signature.
Figure 1

(a) Brief microarray results of lncRNAs. Expression levels of 78,243 lncRNAs were assessed in 6 pairs of SSCC tissues and paired adjacent noncancerous sinonasal tissues using Agilent Human lncRNA 4∗180 K microarrays. Compared with paired adjacent noncancerous tissues, 3146 lncRNAs (4.02%) had significant changes in expression levels (fold change >2, p < 0.05). A total of 874 lncRNAs were excluded due to low expression levels. A total of 3146 lncRNAs were then identified from the screen, with 1174 upregulated and 1098 downregulated. (b) Brief microarray results of mRNAs. Expression levels of 32,776 mRNAs were assessed in 6 pairs of SSCC tissues and paired adjacent noncancerous sinonasal tissues using Agilent Human lncRNA 4∗180 K microarrays. Compared with paired adjacent noncancerous tissues, 2208 mRNAs (6.73%) had significant changes in expression levels (fold change >2, p < 0.05). A total of 284 mRNAs were precluded due to low expression levels. A total of 2208 lncRNAs were then identified from the screen, with 821 upregulated and 1103 downregulated.

Out of the group of RNAs that were upregulated, lncRNA NONHSAT096777 and mRNA HORMAD1 showed the greatest degree of demonstrated upregulation, with 212.076- and 91.757-fold increases, respectively; of those that were downregulated, lncRNA TCONS_l2_00002973 and mRNA ANKRD30A demonstrated the greatest degree of downregulation, with 298.204- and 275.902-fold decreases, respectively (Tables 3 and 4).
Table 3

Top 20 aberrantly expressed lncRNAs in microarray for 6 pairs of SSCC and paired adjacent noncancerous sinonasal tissues.

Probe name p FC (abs)RegulationncRNA accessionGene symbolChr
CUST_13287_PI4295453950.019137239.3843DownNONHSAT096777STATHchr4
CUST_21727_PI4295453880.03946384.90894DownNONHSAT009094PIGRchr1
CUST_76033_PI4295453990.02408682.32558DownNONHSAT013344MSMBchr10
CUST_5401_PI4295454060.02415478.48107DownNONHSAG018364NONHSAG018364chr16
CUST_82017_PI4295453769.06E − 0476.64131DownTCONS_l2_00029708linc-RUSC2chr9
CUST_13257_PI4295453950.01995775.85599DownNONHSAT096773STATHchr4
CUST_13277_PI4295453950.02323474.90795DownNONHSAT096776STATHchr4
CUST_30951_PI4295453959.49E − 0567.20975DownNONHSAT100745CTD-2351A8.1chr5
CUST_91115_PI4295453990.0492465.20921DownNONHSAT017390MUC5Bchr11
CUST_5411_PI4295454060.02019156.05385DownNONHSAT147874ZG16Bchr16
CUST_17568_PI4295454060.0208653.66862DownNONHSAT143547HPchr16
CUST_32391_PI4295453950.00123851.26765DownNONHSAT101166C7chr5
CUST_57295_PI4295453801.32E − 0449.87698DownFR352905FR352905chr19
CUST_15837_PI4295453957.74E − 0447.76275DownNONHSAT097405MMRN1chr4
CUST_32401_PI4295453950.00189341.53056DownNONHSAT101168C7chr5
CUST_58955_PI4295453881.03E − 0540.74976UpNONHSAT075623HOXD11chr2
CUST_72258_PI4295453882.00E − 0439.85786DownNONHSAT087567CHL1chr3
CUST_58985_PI4295453885.09E − 0638.35UpNONHSAT075626HOXD10chr2
CUST_32370_PI4295453950.00745333.21905DownNONHSAG040260NONHSAG040260chr5
CUST_24853_PI4295454100.00304631.34336DownXR_253519.1LOC101928556N/A

FC, fold change; Chr, chromosome; N/A, not annotated.

Table 4

Top 20 aberrantly expressed mRNAs in microarray for 6 pairs of SSCC and paired adjacent noncancerous sinonasal tissues.

Probe name p FC (abs)RegulationGene symbolChrGenbank accession
A_33_P32657830.015708379.6405DownSTATHchr4NM_003154
A_23_P1547840.043979159.44DownBPIFB1chr20NM_033197
A_33_P33003120.034496146.1192DownDMBT1chr10NM_007329
A_24_P8449840.030927119.5701DownPIGRchr1NM_002644
A_23_P865990.02337395.27439DownDMBT1chr10NM_007329
A_24_P1466830.03231789.55136DownMSMBchr10NM_002443
A_33_P32165700.00371675.59971DownMUC5ACN/AAJ298317
A_23_P2183693.92E − 0473.96607DownCCL14chr17NM_032963
A_23_P1182030.01728468.04929DownZG16Bchr16NM_145252
A_21_P00133440.03219661.89528DownAZGP1chr7NM_001185
A_23_P959306.01E − 0558.4917UpHMGA2chr12NM_003483
A_32_P1736620.00206458.24841DownCRISP2chr6NM_003296
A_23_P3626940.03661854.65685DownC4orf7chr4NM_152997
A_33_P32452280.03198852.29204DownBPIFA1chr20NM_130852
A_23_P582280.01730450.18366DownODAMchr4NM_017855
A_23_P4299981.13E − 0448.27517DownFOSBchr19NM_006732
A_33_P32330400.01225242.21305DownSERPINB11chr18NM_080475
A_23_P87020.01837740.33374DownPIPchr7NM_002652
A_33_P32757021.49E − 0533.86336DownFMO2chr1NM_001460
A_21_P00000030.00653231.00913DownPRR4chr12NM_007244

FC, fold change; Chr, chromosome; NA, not annotated.

Hierarchical clustering of the lncRNAs and mRNAs profile was performed using cluster 3.0.2; hierarchical clustering of the expression of the top 100 dysregulated lncRNAs and top dysregulated 100 mRNAs based on centered Pearson correlation clearly separated SSCC tissues from corresponding normal tissues (Figure 2).
Figure 2

Heat map of lncRNAs and mRNAs that were often aberrantly expressed in SSCC compared with paired adjacent noncancerous sinonasal tissues. (a) Hierarchical clustering analysis of the top 100 dysregulated lncRNAs. (b) Hierarchical clustering analysis of the top 100 dysregulated mRNAs. Each row represents one lncRNA or mRNA, and each column represents one tissue sample. The relative lncRNA or mRNA expression is depicted according to the color scale. Red indicates elevated expression and green indicates reduced expression. 2, 0 and −2 are fold changes in the corresponding spectrum. Carcinoma group (A3, F5, D6, F2, F9, and D2). Paired adjacent noncancerous group (D9, F1, G10, B2, G2, and H2).

3.2. lncRNA-mRNA Coexpression Network

We constructed the lncRNA-mRNA coexpression network to identify the interactions between mRNAs and lncRNAs. The results showed that the coexpression network was composed of 787 network nodes and 8478 connections between 445 lncRNAs and 342 mRNAs. Within this coexpression network, 7635 pairs connections presented as positive, and 843 pairs connections presented as negative (Figure 3). This coexpression network indicated that one lncRNA (NONHSAT041869) could target 118 mRNAs/mRNAs at most and one mRNA (EXO1) could correlate with 122 lncRNAs/mRNAs at most. The results implied that EXO1, CDCA5, and BUB1B may play key roles in SSCC process and development.
Figure 3

lncRNA-mRNA coexpression network. The SSCC consisted of coexpression relationships between lncRNAs and mRNAs. The red circles denote mRNAs and the blue circles denote lncRNAs. The node degree is indicated by the circle size. An edge represents a coexpression relationship between mRNA and a lncRNA in the context of SSCC progression.

3.3. Function Analysis of Differentially Expressed Genes

Functional roles of lncRNAs can only be indirectly predicted by analyzing the functions of their coexpressed mRNAs, because most lncRNAs' functions have not yet been defined. To investigate underlying biological associations, we ran GO and KEGG pathway analysis on the top 500 differentially expressed lncRNAs and mRNAs. GO analysis indicated that these differentially expressed genes were enriched in 12 biological processes; the majority were proven to be related to cancer-associated biological behaviors; the top 3 were multicellular organismal development, mitotic cell cycle, and cell cycle. The differentially expressed genes also were enriched in 12 cellular components; the top 3 were nucleus, extracellular region, and cytosol. Similarly, 12 molecular functions were enriched for including protein binding, DNA binding, and ATP binding. KEGG analysis revealed pathways associated with cancer, such as microRNAs in cancer, p53 signaling pathway, and PI3K-Akt signaling pathway (Figures 4(a)–4(d)).
Figure 4

GO and KEGG pathway analysis. (a)–(c) Top 10 enrichment GO terms for differentially expressed mRNAs. The bar plot shows the enrichment scores (−lg(p value)) of the significant enrichment GO terms. (a) GO terms of biological process (BP); (b) GO terms of cellular component (CC); (c) GO terms of molecular function (MF). (d) Top 10 pathways of differentially expressed mRNAs in SSCC. The vertical axis represents the pathway category and the horizontal axis represents the enrichment score (−lg(p value)) of the pathway.

3.4. Gene Signal-Network

We performed a signal-net analysis to investigate the global network, based on the significantly regulated KEGG. With signal-net, we screened the important dysregulated genes involved in the differences between SSCC and normal tissues (Figure 5). The results showed that the core genes may have played an important role in SSCC process. According to the results of this analysis, the top 3 betweenness genes were MAPK12, RAPGEF3, and KIT.
Figure 5

Signal-net. The interaction network of differentially expressed genes (signal-net). The circles represent important functional genes in SSCC (blue: downregulated genes; red: upregulated genes); the circle size represents the degree of interaction (betweenness centrality); the lines indicate the interactions.

3.5. qRT-PCR Validation

Five differentially expressed lncRNAs were randomly selected for validation by means of qRT-PCR according to the manufacturer's recommendations. NONHSAT125629 and TCONS_l2_00030809 were upregulated and NONHSAT066780, NONHSAG040260, and NONHSAG043195 were downregulated in SSCC. The results of qRT-PCR were consistent with those of the microarray. All of the 5 lncRNAs were differentially expressed with the same trend (up- or downregulated) (Figure 6).
Figure 6

qRT-PCR validation. qRT-PCR verification of 5 candidate lncRNAs in 22 pairs of SSCC tissues. The y-axis represents the relative expression levels of lncRNAs. Paired t-tests (2-tailed) were performed to compare the expression levels between carcinoma (C) and noncancerous tissues (N), and a p value <0.05 indicated statistical significance.

4. Discussion

SSCC is a rare disease arising in the epithelium of respiratory tract and is very poorly studied from the molecular perspective. To date, the pathogenesis of SSCC remains unclear due to its low incidence. Only a few studies have focused on its pathogenesis and potential molecular targets for therapy, specifically microRNAs [10-12]. Recently, studies have increasingly shown that many types of tumors are closely associated with the abnormal expression of lncRNAs [6-9]. In head and neck cancer, tongue cancer [13], laryngeal cancer [14], nasopharyngeal cancer [15], and thyroid cancer [6] are all associated with the abnormal expression of lncRNAs. However, to the best of our knowledge, there are no reports on lncRNA expression profiles in SSCC. Here, we investigated the lncRNA and mRNA expression profiles of SSCC samples from patients using microarray analysis. We identified thousands of lncRNAs that are expressed significantly differently in SSCC compared to adjacent noncancerous tissues, including both upregulation and downregulation. To some extent, false positive results do exist in the microarray detection. Therefore, 5 lncRNAs were randomly selected to validate the microarray results. Consistent with the microarray results, all of the 5 lncRNAs were differentially expressed based on the results of qRT-PCR. In this study, we used GO and KEGG pathway analyses to identify biological functions enriched among the differentially expressed mRNAs. We found that these mRNAs were involved in a lot of cancer-associated biological processes, cellular components, and molecular functions. The GO annotation indicated that these gene products may affect the tumorigenesis and development of SSCC. The KEGG pathway analysis identified that many pathways were related to cancer, such as microRNAs in cancer, P53 signaling pathway, PI3K-Akt signaling pathway. For example, it has been documented that the p53 signaling pathway is activated in many solid tumors, including SSCC [1, 16, 17]. In the present study, p53 signaling pathway was related to lncRNA NONHSAT125629. This molecule may participate in numerous biological processes, including mitotic cell cycle, cell division, DNA replication, G1/S transition of mitotic cell cycle, and G2/M transition of mitotic cell cycle. The global network (gene signal-network) and lncRNA-mRNA network structure analysis were established to show the core genes that play a critical role in this SSCC gene network. However, how these genes participate in the pathogenesis of SSCC largely remains unknown. The analysis revealed that MAPK12, RAPGEF3, and KIT exhibited the most betweenness centrality and all were related to the cancer progression. Thus, our preliminary data provide a justification for the involvement of these genes in SSCC development. For example, KIT is associated with various pathways related to cancer, such as pathways in cancer and PI3K-Akt signaling pathway. Mutations in this gene are associated with gastrointestinal stromal tumors [18], lung cancer [19], and breast cancer [20]. The limitation of this study lies in the fact that the sample size is relatively small. Our results require further validation in larger prospective patient cohorts and functional experiments, both in vitro and in vivo. Our results provide some valuable clues for future function and mechanism studies of SSCC.

5. Conclusions

In summary, to our knowledge, our study is the first screening and analysis of lncRNA expression profile in SSCC. The results show that genes regulated by these lncRNAs are involved in cancer pathways as a proof of principle. This may offer new insights into pathogenesis and could be a promising way to dissect the molecular pathogenesis of this refractory cancer. Our study lays the foundation for further investigation of this disease. Further large scale studies are warranted to provide convincing evidence for clarifying the functions of lncRNAs in SSCC and determining whether these lncRNAs can serve as new diagnostic biomarkers, prognostic factors for survival, and therapeutic targets in SSCC.
  20 in total

1.  Genome-wide analysis of long noncoding RNA expression profile in papillary thyroid carcinoma.

Authors:  Xiabin Lan; Hao Zhang; Zhihong Wang; Wenwu Dong; Wei Sun; Liang Shao; Ting Zhang; Dalin Zhang
Journal:  Gene       Date:  2015-05-21       Impact factor: 3.688

2.  Identification of novel molecular targets regulated by tumor suppressive miR-1/miR-133a in maxillary sinus squamous cell carcinoma.

Authors:  Nijiro Nohata; Toyoyuki Hanazawa; Naoko Kikkawa; Daiju Sakurai; Keita Sasaki; Takeshi Chiyomaru; Kazumori Kawakami; Hirofumi Yoshino; Hideki Enokida; Masayuki Nakagawa; Yoshitaka Okamoto; Naohiko Seki
Journal:  Int J Oncol       Date:  2011-06-23       Impact factor: 5.650

3.  Mutations in TP53 tumor suppressor gene in wood dust-related sinonasal cancer.

Authors:  Reetta Holmila; Jette Bornholdt; Pirjo Heikkilä; Tuula Suitiala; Joëlle Févotte; Diane Cyr; Johnni Hansen; Satu-Marja Snellman; Michael Dictor; Torben Steiniche; Vivi Schlünssen; Thomas Schneider; Eero Pukkala; Kai Savolainen; Henrik Wolff; Håkan Wallin; Danièle Luce; Kirsti Husgafvel-Pursiainen
Journal:  Int J Cancer       Date:  2010-08-01       Impact factor: 7.396

4.  Paranasal sinus squamous cell carcinoma incidence and survival based on Surveillance, Epidemiology, and End Results data, 1973 to 2009.

Authors:  Benjamin Ansa; Michael Goodman; Kevin Ward; Scott A Kono; Taofeek K Owonikoko; Kristin Higgins; Jonathan J Beitler; William Grist; Trad Wadsworth; Mark El-Deiry; Amy Y Chen; Fadlo Raja Khuri; Dong M Shin; Nabil F Saba
Journal:  Cancer       Date:  2013-05-14       Impact factor: 6.860

5.  Human papillomaviruses are identified in a subgroup of sinonasal squamous cell carcinomas with favorable outcome.

Authors:  Llucia Alos; Susana Moyano; Alfons Nadal; Isam Alobid; Jose L Blanch; Edgar Ayala; Belén Lloveras; Wim Quint; Antonio Cardesa; Jaume Ordi
Journal:  Cancer       Date:  2009-06-15       Impact factor: 6.860

6.  Tumour suppressive microRNA-874 regulates novel cancer networks in maxillary sinus squamous cell carcinoma.

Authors:  N Nohata; T Hanazawa; N Kikkawa; D Sakurai; L Fujimura; T Chiyomaru; K Kawakami; H Yoshino; H Enokida; M Nakagawa; A Katayama; Y Harabuchi; Y Okamoto; N Seki
Journal:  Br J Cancer       Date:  2011-08-16       Impact factor: 7.640

7.  Long Noncoding RNA Expression Signatures of Metastatic Nasopharyngeal Carcinoma and Their Prognostic Value.

Authors:  Wei Zhang; Lin Wang; Fang Zheng; Ruhai Zou; Changqing Xie; Qiannan Guo; Qian Hu; Jianing Chen; Xing Yang; Herui Yao; Erwei Song; Yanqun Xiang
Journal:  Biomed Res Int       Date:  2015-09-13       Impact factor: 3.411

8.  Establishment and genetic characterization of six unique tumor cell lines as preclinical models for sinonasal squamous cell carcinoma.

Authors:  Cristina García-Inclán; Alejandro López-Hernández; Marta Alonso-Guervós; Eva Allonca; Sira Potes; Santiago Melón; Fernando López; José Luis Llorente; Mario Hermsen
Journal:  Sci Rep       Date:  2014-05-12       Impact factor: 4.379

9.  Long non-coding RNA profiling in laryngeal squamous cell carcinoma and its clinical significance: potential biomarkers for LSCC.

Authors:  Zhisen Shen; Qun Li; Hongxia Deng; Dakai Lu; Haojun Song; Junming Guo
Journal:  PLoS One       Date:  2014-09-22       Impact factor: 3.240

10.  The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling.

Authors:  Laurence Booth; Jane L Roberts; Mehrad Tavallai; Timothy Webb; Daniel Leon; Jesse Chen; William P McGuire; Andrew Poklepovic; Paul Dent
Journal:  Oncotarget       Date:  2016-04-12
View more
  2 in total

1.  A transcriptome profile in gallbladder cancer based on annotation analysis of microarray studies.

Authors:  Chunlin Ge; Xuan Zhu; Xing Niu; Bingye Zhang; Lijie Chen
Journal:  Mol Med Rep       Date:  2020-11-12       Impact factor: 2.952

2.  Down-regulating NEAT1 inhibited the viability and vasculogenic mimicry formation of sinonasal squamous cell carcinoma cells via miR-195-5p/VEGFA axis.

Authors:  Honglue Lu; Fei Kang
Journal:  Biosci Rep       Date:  2020-11-27       Impact factor: 3.840

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.